A Case Report of Locally Advanced Non-Small Cell Lung Cancer Treated with Lorlatinib to Achieve R0 Resection
1. Abstract Anaplastic Lymphoma Kinase-Tyrosine Kinase Inhibitors (ALK TKIs) are highly effective in treating ALK-positive patients with advanced non-small cell lung cancer (NSCLC). However.